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The adenoviral AdDD mutant enhances mitoxantrone-induced cell death
by promoting apoptosis and attenuating autophagy in prostate cancer
cells.
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The	   adenoviral	   AdΔΔ	   mutant	   enhances	   mitoxantrone-­‐induced	   cell	   death	   by	  
promoting	  apoptosis	  and	  attenuating	  autophagy	  in	  prostate	  cancer	  cells.	  Authors:	  Carmen	  Aguirre	  Hernandez	  and	  Gunnel	  Halldén	  Prostate	   cancer	   (PCa)	   is	   the	   second	   cancer	   killer	   in	   men	   globally	   due	   to	   the	   rapid	  development	   of	   resistance	   to	   all	   available	   therapies.	   Late-­‐stage	   metastatic	   disease	   is	  incurable.	  In	  response	  to	  cytotoxic	  drugs	  autophagy	  is	  frequently	  induced	  in	  cancer	  cell	  as	  a	  rescue	  mechanism	  and	  may	  contribute	  to	  the	  development	  of	  drug-­‐resistance.	  We	  previously	   demonstrated	   that	   the	   oncolytic	   adenoviral	   mutant	   Ad∆∆,	   in	   combination	  with	  cytotoxic	  drugs,	  effectively	  kills	  resistant	  prostate	  cancer	  cells	  but	  not	  normal	  cells.	  AdΔΔ	   is	  deleted	   in	   the	  pRb-­‐binding	  E1ACR2-­‐region	  and	   in	   the	  anti-­‐apoptotic	  E1B19K-­‐gene	  for	  tumour	  selectivity	  and	  apoptosis	  induction,	  respectively.	  Ad∆∆	  in	  combination	  with	   drugs	   currently	   used	   clinically	   to	   treat	   PCa,	   mitoxantrone	   or	   docetaxel,	   causes	  synergistically	   enhanced	   cell	   killing	   by	   increasing	   apoptosis.	   Here,	   we	   investigated	  whether	   the	   increased	   apoptosis	   was	   dependent	   on	   attenuation	   of	   drug-­‐induced	  autophagy.	  	  We	   found	   that	   mitoxantrone	   and	   docetaxel	   potently	   stimulated	   the	   initiation	   of	  autophagy	  by	  promoting	  the	  conversion	  of	  LC3I	  to	  LC3II	   in	  both	  22Rv1	  and	  PC3	  cells.	  Simultaneous	  infection	  with	  Ad∆∆	  promoted	  apoptotic	  cell	  death	  while	  preventing	  LC3I	  to	   LC3II	   conversion	   but	   did	   not	   affect	   basal	   autophagy.	   Addition	   of	   the	   autophagy	  inhibitor	   chloroquine	   further	   increased	   the	   apoptotic	   cell	   killing	  while	   the	   autophagy	  inducer	   rapamycin	   decreased	   cell	   killing.	   The	   Ad∆∆-­‐mediated	   attenuation	   of	   drug-­‐induced	  autophagy	  was	  mimicked	  by	  overexpression	  of	  the	  small	  viral	  E1A12S	  protein.	  Silencing	  of	  the	  autophagy	  regulator	  Bcl2	  reverted	  Ad∆∆	  sensitization	  to	  mitoxantrone	  and	  promoted	  autophagy.	  In	   conclusion,	   our	   data	   suggest	   that	   inhibition	   of	   autophagy	   in	   combination	   with	  cytotoxic	  drugs	  is	  a	  promising	  therapeutic	  strategy	  for	  late-­‐stage	  prostate	  cancer.	  	  	  
